TRIUMEQ is a prescription HIV-1 (Human Immunodeficiency Virus-type 1) medicine used to treat HIV-1 infection in adults and in children who weigh at least 88 pounds. HIV-1 is the virus that causes AIDS. TRIUMEQ is not for use by itself in people who have or have had resistance to abacavir, dolutegravir, or lamivudine. It is not known if TRIUMEQ is safe and effective in children who weigh less than 88 pounds.

TRIUMEQ is a prescription HIV-1 (Human Immunodeficiency Virus-type 1) medicine used to treat HIV-1 infection in adults and in children who weigh at least 88 pounds. Continued below.

Could you move forward with TRIUMEQ as your HIV-1 treatment?

4 things to consider about TRIUMEQ

TRIUMEQ may help you reach and maintain an undetectable viral load. Undetectable means reducing the HIV in your blood to very low levels. Results may vary.

TRIUMEQ can be taken day or night, around the same time each day.

TRIUMEQ is one pill, taken once a day. TRIUMEQ is not for use by itself in some people. Take TRIUMEQ exactly as your healthcare provider tells you.

You can take TRIUMEQ with or without food.

 

4 things to consider about TRIUMEQ

TRIUMEQ may help you reach and maintain an undetectable viral load.

Undetectable means reducing the HIV in your blood to very low levels. Results may vary.

TRIUMEQ is one pill, taken once a day. TRIUMEQ is not for use by itself in some people. Take TRIUMEQ exactly as your healthcare provider tells you.

TRIUMEQ can be taken day or night, around the same time each day.

You can take TRIUMEQ with or without food.

 

How to pronounce TRIUMEQ: TRI-u-meck Here are some things to ask your doctor

TRIUMEQ is a prescription HIV-1 (Human Immunodeficiency Virus-type 1) medicine used to treat HIV-1 infection in adults and in children who weigh at least 88 pounds. HIV-1 is the virus that causes AIDS. TRIUMEQ is not for use by itself in people who have or have had resistance to abacavir, dolutegravir, or lamivudine. It is not known if TRIUMEQ is safe and effective in children who weigh less than 88 pounds.

How to pronounce TRIUMEQ: TRI-u-meck
Here are some things to ask your doctor

The HLA-B*5701 screening test

Before you take TRIUMEQ, your doctor will give you a genetic screening test if you have not already had one. If you test positive for the HLA-B*5701 gene variation, you can't take TRIUMEQ.

If your
HLA-B*5701 test
is POSITIVE
  • You have the HLA-B*5701 gene variation.
  • This means you should not take medicines containing abacavir, including TRIUMEQ.
  • You have a much higher risk for a serious allergic reaction (hypersensitivity reaction) that can cause death if you take medicines containing abacavir, including TRIUMEQ.

 

If your
HLA-B*5701 test
is POSITIVE
  • You have the HLA-B*5701 gene variation.
  • This means you should not take medicines containing abacavir, including TRIUMEQ.
  • You have a much higher risk for a serious allergic reaction (hypersensitivity reaction) that can cause death if you take medicines containing abacavir, including TRIUMEQ.

 

If your
HLA-B*5701 test
is NEGATIVE
  • You do not have the HLA-B*5701 gene variation.
  • You may still have a hypersensitivity reaction to TRIUMEQ, though the risk is much lower.
  • Ask your doctor if a medicine containing abacavir, like TRIUMEQ, may be right for you.
If your
HLA-B*5701 test
is NEGATIVE
  • You do not have the HLA-B*5701 gene variation.
  • You may still have a hypersensitivity reaction to TRIUMEQ, though the risk is much lower.
  • Ask your doctor if a medicine containing abacavir, like TRIUMEQ, may be right for you.

TRIUMEQ by the numbers

Clinical information about TRIUMEQ: SINGLE Study

SINGLE is a medical study of 833 adult patients living with HIV-1 who had never taken HIV-1 treatment before. In that study, more patients got to undetectable (less than 50 copies of HIV-1 RNA in a mL of blood) with TRIUMEQ than with Atripla®. The difference in results was mostly due to more patients on Atripla stopping their medicine because of side effects than patients on TRIUMEQ.

Your results may vary.

SINGLE STUDY RESULTS 
AT 144 WEEKS 
(ABOUT 3 YEARS):

TRIUMEQ

ATRIPLA

71%

of patients who took TRIUMEQ reached undetectable (less than 50 copies of HIV-1 in a mL of blood).

63%

of patients who took Atripla reached undetectable (less than 50 copies of HIV-1 in a mL of blood).

378 cells/mm3 was the average increase in CD4+ T-cell count* in patients who took TRIUMEQ.

 

332 cells/mm3 was the average increase in CD4+ T-cell count* in patients who took Atripla.

 

4%

of patients stopped taking TRIUMEQ because of side effects.

14%

of patients stopped taking Atripla because of side effects.

TRIUMEQ

71%

of patients who took TRIUMEQ reached undetectable (less than 50 copies of HIV-1 in a mL of blood).

378 cells/mm3 was the average increase in CD4+ T-cell count* in patients who took TRIUMEQ.

 

4%

of patients stopped taking TRIUMEQ because of side effects.

ATRIPLA

63%

of patients who took Atripla reached undetectable (less than 50 copies of HIV-1 in a mL of blood).

332 cells/mm3 was the average increase in CD4+ T-cell count* in patients who took Atripla.

 

14%

of patients stopped taking Atripla because of side effects.

*CD4+ T-cells (also called T-cells) are white blood cells that help fight infections. CD4 cell count is the number of CD4+ T-cells per mm3 of blood.

MOST COMMON MEDIUM TO SEVERE SIDE EFFECTS NOTED IN SINGLE STUDY OCCURRING AT A FREQUENCY OF AT LEAST 2% AT 144 WEEKS (ABOUT 3 YEARS):

TRIUMEQ

ATRIPLA

3%

of patients experienced trouble sleeping.

3%

of patients experienced trouble sleeping.

2%

of patients experienced headaches.

2%

of patients experienced headaches.

2%

of patients experienced tiredness.

2%

of patients experienced tiredness.

TRIUMEQ

3%

of patients experienced trouble sleeping.

2%

of patients experienced headaches.

2%

of patients experienced tiredness.

ATRIPLA

3%

of patients experienced trouble sleeping.

2%

of patients experienced headaches.

2%

of patients experienced tiredness.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Clinical information about TRIUMEQ in women: ARIA Study

ARIA was a 48-week medical study with 495 adult women who had never taken HIV-1 medicines before. The women were split into two groups: one group was given TRIUMEQ and the other group was given Reyataz®/Norvir®/Truvada®.

ARIA was an open-label study, so both the patients and the healthcare providers knew which medicine the patients were taking.

Your results may vary.

ARIA STUDY RESULTS AT 48 WEEKS
(ABOUT A YEAR):

TRIUMEQ

REYATAZ + NORVIR + TRUVADA

82% 

of women who took TRIUMEQ reached undetectable (less than 50 copies of HIV-1 in a mL of blood).

71%

of women who took Reyataz + Norvir + Truvada reached undetectable (less than 50 copies of HIV-1 in a mL of blood).

234 cells/mm3 was the average increase in CD4+ T-cell count* in women who took TRIUMEQ.

 

200 cells/mm3 was the average increase in CD4+ T-cell count* in women who took Reyataz + Norvir + Truvada.

 

4%

of women taking TRIUMEQ stopped taking it because of side effects.

7%

of women taking Reyataz + Norvir + Truvada stopped taking it because of side effects.

TRIUMEQ

82% 

of women who took TRIUMEQ reached undetectable (less than 50 copies of HIV-1 in a mL of blood).

234 cells/mmwas the average increase in CD4+ T-cell count* in women who took TRIUMEQ.

 

4%

of women taking TRIUMEQ stopped taking it because of side effects.

REYATAZ + NORVIR + TRUVADA

71%

of women who took Reyataz + Norvir + Truvada reached undetectable (less than 50 copies of HIV-1 in a mL of blood).

200 cells/mm3 was the average increase in CD4+ T-cell count* in women who took Reyataz + Norvir + Truvada.

 

7%

of women taking Reyataz + Norvir + Truvada stopped taking it because of side effects.

*CD4+ T-cells (also called T-cells) are white blood cells that help fight infections. CD4 cell count is the number of CD4+ T-cells per mm3 of blood.

MOST COMMON MEDIUM TO SEVERE SIDE EFFECTS FROM THE ARIA STUDY AT A FREQUENCY OF AT LEAST 2% AT 48 WEEKS 
(ABOUT A YEAR):

TRIUMEQ

REYATAZ + NORVIR + TRUVADA

1%

of patients experienced nausea.

 

4%

of patients experienced nausea.

1%

of patients experienced headaches.

 

2%

of patients experienced headaches.

 

1%

of patients experienced rash.

4%

of patients experienced rash.

TRIUMEQ

1%

of patients experienced nausea.

 

1%

of patients experienced headaches.

 

1%

of patients experienced rash.

REYATAZ + NORVIR + TRUVADA

4%

of patients experienced nausea.

2%

of patients experienced headaches.

4%

of patients experienced rash.

Includes rash, rash with bumps, and itchy rash.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.